Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
EYPT Stock Forecast 2026-2027
$13.85
Current Price
$1.16B
Market Cap
Buy 13
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to EYPT Price Targets
+391.0%
To High Target of $68.00
+159.9%
To Median Target of $36.00
+44.4%
To Low Target of $20.00
EYPT Price Momentum
-5.9%
1 Week Change
+5.3%
1 Month Change
+34.5%
1 Year Change
-24.2%
Year-to-Date Change
-27.5%
From 52W High of $19.11
+47.3%
From 52W Low of $9.40
📊 TOP ANALYST CALLS
Did EYPT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if EyePoint is one of their latest high-conviction picks.
Latest EYPT Stock Price Targets & Analyst Predictions
Based on our analysis of 7 Wall Street analysts, EYPT has a bullish consensus with a median price target of $36.00 (ranging from $20.00 to $68.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $13.85, the median forecast implies a 159.9% upside. This outlook is supported by 13 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
EYPT Analyst Ratings
13
Buy
0
Hold
0
Sell
EYPT Price Target Range
Low
$20.00
Average
$36.00
High
$68.00
Current: $13.85
Latest EYPT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for EYPT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jul 8, 2026 | Cantor Fitzgerald | Steve Seedhouse | Overweight | Assumes | $47.00 |
| Jul 1, 2026 | Chardan Capital | Andreas Argyrides | Buy | Maintains | $65.00 |
| Jun 24, 2026 | Guggenheim | Buy | Reiterates | $N/A | |
| May 7, 2026 | RBC Capital | Outperform | Maintains | $N/A | |
| Mar 9, 2026 | Citigroup | Buy | Maintains | $N/A | |
| Mar 5, 2026 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Mar 4, 2026 | Chardan Capital | Buy | Maintains | $N/A | |
| Nov 6, 2025 | RBC Capital | Outperform | Maintains | $N/A | |
| Aug 7, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Aug 6, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Jun 17, 2025 | RBC Capital | Outperform | Initiates | $N/A | |
| May 29, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| May 16, 2025 | Mizuho | Outperform | Maintains | $N/A | |
| May 8, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Mar 6, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Mar 6, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Feb 6, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Jan 7, 2025 | Citigroup | Buy | Initiates | $N/A | |
| Dec 5, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 11, 2024 | Baird | Outperform | Maintains | $N/A |
EyePoint Pharmaceuticals Inc. (EYPT) Competitors
The following stocks are similar to EyePoint based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
EyePoint Pharmaceuticals Inc. (EYPT) Financial Data
EyePoint Pharmaceuticals Inc. has a market capitalization of $1.16B with a P/E ratio of -4.4x. The company generates $7.61M in trailing twelve-month revenue with a 93.4% profit margin.
Revenue growth is +161.7% quarter-over-quarter, while maintaining an operating margin of -450.7% and return on equity of -102.7%.
Valuation Metrics
Market Cap
$1.16B
Enterprise Value
$1.29B
P/E Ratio
-4.4x
PEG Ratio
-0.1x
Price/Sales
152.5x
Growth & Margins
Revenue Growth (YoY)
+161.7%
Gross Margin
+24.1%
Operating Margin
-450.7%
Net Margin
+93.4%
EPS Growth
-97.2%
Financial Health
Cash/Price Ratio
+3.4%
Current Ratio
6.7x
Debt/Equity
46.8x
ROE
-102.7%
ROA
-54.1%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
EyePoint Pharmaceuticals Inc. (EYPT) Business Model
About EyePoint Pharmaceuticals Inc.
What They Do
Develops innovative ophthalmic biopharmaceutical products.
Business Model
EyePoint Pharmaceuticals generates revenue by developing and commercializing ophthalmic products that treat serious eye disorders. The company employs unique drug delivery technologies to create sustained-release treatments, which allow for prolonged therapeutic effects and improved patient outcomes. Their business model focuses on addressing unmet medical needs in the ophthalmology sector through collaborations with leading eye care companies.
Additional Information
Based in Watertown, Massachusetts, EyePoint Pharmaceuticals is actively involved in advancing therapeutic research and expanding access to novel solutions for visual impairment. The company plays a significant role in the biotechnology and healthcare sectors, contributing to the global advancement of vision-related healthcare.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
165
CEO
Dr. Jay S. Duker M.D.
Country
United States
IPO Year
2018
Website
eyepointpharma.comEyePoint Pharmaceuticals Inc. (EYPT) Latest News & Analysis
Latest News
EyePoint Appoints Tarek S. Hassan, M.D.
3 days ago
Quick Summary
A prominent retina specialist has been appointed to offer strategic guidance on clinical development, commercialization, and pipeline initiatives for a company, indicating potential growth opportunities.
Why It Matters
The appointment of a key opinion leader in retina care signals potential advancements in product development, enhancing the company's market position and driving investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Robinhood Markets is a top stock pick for July, alongside Micron and Oracle, according to Mizuho Securities.
Why It Matters
Robinhood's inclusion as a top stock indicates positive sentiment and potential growth, while Micron and Oracle being favored suggests strong performance expectations in tech.
Source: Barrons
Market Sentiment:
Positive
Quick Summary
ADMA Biologics is profitable with potential for near-term growth. EyePoint Pharmaceuticals may emerge as a significant player in a $15 billion global market.
Why It Matters
ADMA Biologics' profitability and growth potential indicate strong financial health, while EyePoint Pharmaceuticals' market positioning suggests significant revenue opportunities, enhancing investor confidence.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
EyePoint, Inc. (Nasdaq: EYPT) granted non-statutory stock options to new employees as inducement awards, compliant with NASDAQ Listing Rule 5635(c)(4).
Why It Matters
EyePoint's stock options for new employees indicate growth and confidence in attracting talent, potentially enhancing innovation and future profitability, impacting share performance positively.
Source: GlobeNewsWire
Market Sentiment:
Neutral
EyePoint, Inc. (EYPT) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
1 month ago
Quick Summary
EyePoint, Inc. (EYPT) presented at the Goldman Sachs 47th Annual Global Healthcare Conference, highlighting its developments and strategies within the healthcare sector.
Why It Matters
EyePoint's presentation at a major healthcare conference can signal potential growth opportunities, investor interest, and possible partnerships, influencing stock performance and market perception.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Eyepoint Pharmaceuticals (EYPT) plans to report top-line data from its Phase 3 trial for DURAVYU (EYP-1901) starting in August, with a second pivotal trial expected two months later.
Why It Matters
Positive Phase 3 data for EYPT's DURAVYU could boost stock value, attract investor interest, and influence future funding and partnerships in the biotech sector.
Source: MarketBeat
Market Sentiment:
Neutral
Frequently Asked Questions About EYPT Stock
What is EyePoint Pharmaceuticals Inc.'s (EYPT) stock forecast for 2027?
Based on our analysis of 7 Wall Street analysts, EyePoint Pharmaceuticals Inc. (EYPT) has a median price target of $36.00. The highest price target is $68.00 and the lowest is $20.00.
Is EYPT stock a good investment in 2027?
According to current analyst ratings, EYPT has 13 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $13.85. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for EYPT stock?
Wall Street analysts predict EYPT stock could reach $36.00 in the next 12 months. This represents a 159.9% increase from the current price of $13.85. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is EyePoint Pharmaceuticals Inc.'s business model?
EyePoint Pharmaceuticals generates revenue by developing and commercializing ophthalmic products that treat serious eye disorders. The company employs unique drug delivery technologies to create sustained-release treatments, which allow for prolonged therapeutic effects and improved patient outcomes. Their business model focuses on addressing unmet medical needs in the ophthalmology sector through collaborations with leading eye care companies.
What is the highest forecasted price for EYPT EyePoint Pharmaceuticals Inc.?
The highest price target for EYPT is $68.00 from at , which represents a 391.0% increase from the current price of $13.85.
What is the lowest forecasted price for EYPT EyePoint Pharmaceuticals Inc.?
The lowest price target for EYPT is $20.00 from at , which represents a 44.4% increase from the current price of $13.85.
What is the overall EYPT consensus from analysts for EyePoint Pharmaceuticals Inc.?
The overall analyst consensus for EYPT is bullish. Out of 7 Wall Street analysts, 13 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $36.00.
How accurate are EYPT stock price projections?
Stock price projections, including those for EyePoint Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 1:24 PM UTC